AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available
AI for Exam Proctoring and Security  - Part-Time Jobs Available

AI for Exam Proctoring and Security - Part-Time Jobs Available

₹1633

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Achieve up to 100% returns with just ₹500. Invest smart, earn big!

quantity
Add to Wishlist
Product Description

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Achieve up to 100% returns with just ₹500. Invest smart, earn big!

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Achieve up to 100% returns with just ₹500. Invest smart, earn big!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Start your investment journey with ₹500. Watch your returns multiply monthly!We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Invest ₹500 and enjoy fast, secure monthly profits. Start now!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Turn ₹500 into big monthly profits. Start today with our smart investment tools!The underperformance persists despite a 22.AI for Exam Proctoring and Security ✌️【Fixed Income】✌️Begin investing today with ₹500 and achieve reliable, high returns every month.

Related Products